SEEDSUPPLY

SEEDSUPPLY researches and develops medical and agrochemical products. The company, a subsidiary of Takeda Pharmaceutical Company Limited, was established in May 2017. It has proposed an agile small-molecule drug discovery process that utilizes binder selection technology as a proprietary compound screening method. This technology enables compound screening for any protein or RNA, providing drug discovery seeds for a variety of drug discovery targets, including those where biochemical activity measurement is challenging. Additionally, a binding compound database built for specific drug discovery target classes will be used for target selection, enhancing the efficiency and success rate of the drug discovery process. Furthermore, this database holds potential for broader applications.